CN109640983A - 醛捕获化合物和其用途 - Google Patents

醛捕获化合物和其用途 Download PDF

Info

Publication number
CN109640983A
CN109640983A CN201780051309.5A CN201780051309A CN109640983A CN 109640983 A CN109640983 A CN 109640983A CN 201780051309 A CN201780051309 A CN 201780051309A CN 109640983 A CN109640983 A CN 109640983A
Authority
CN
China
Prior art keywords
compound
disease
patient
condition
illness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780051309.5A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·吉图·马哈塔
斯科特·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aldeyra Therapeutics Inc
Original Assignee
Aldexa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldexa Therapeutics Inc filed Critical Aldexa Therapeutics Inc
Publication of CN109640983A publication Critical patent/CN109640983A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
CN201780051309.5A 2016-08-22 2017-08-22 醛捕获化合物和其用途 Pending CN109640983A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378065P 2016-08-22 2016-08-22
US62/378,065 2016-08-22
PCT/US2017/047945 WO2018039192A1 (en) 2016-08-22 2017-08-22 Aldehyde trapping compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN109640983A true CN109640983A (zh) 2019-04-16

Family

ID=61190657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051309.5A Pending CN109640983A (zh) 2016-08-22 2017-08-22 醛捕获化合物和其用途

Country Status (9)

Country Link
US (2) US20180050989A1 (cg-RX-API-DMAC7.html)
EP (1) EP3500256A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019532029A (cg-RX-API-DMAC7.html)
CN (1) CN109640983A (cg-RX-API-DMAC7.html)
AU (1) AU2017317524A1 (cg-RX-API-DMAC7.html)
CA (1) CA3032521A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019001625A2 (cg-RX-API-DMAC7.html)
MX (1) MX2019001722A (cg-RX-API-DMAC7.html)
WO (1) WO2018039192A1 (cg-RX-API-DMAC7.html)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111356451A (zh) * 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
WO2021136244A1 (zh) * 2019-12-30 2021-07-08 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
CN113784954A (zh) * 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
WO2022143489A1 (zh) * 2020-12-29 2022-07-07 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
CN115551507A (zh) * 2020-04-13 2022-12-30 奥尔德拉医疗公司 用于治疗肺、肝脏和肾脏疾病、病症或病况的喹啉化合物
CN115697336A (zh) * 2020-05-13 2023-02-03 奥尔德拉医疗公司 药物制剂及其用途
CN115843293A (zh) * 2021-06-25 2023-03-24 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US12128013B2 (en) 2013-01-23 2024-10-29 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US12240816B2 (en) 2015-08-21 2025-03-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2025140390A1 (zh) * 2023-12-28 2025-07-03 珠海联邦制药股份有限公司 Rasp抑制剂在制备治疗或预防慢性咳嗽、哮喘及酒精性肝病疾病的药物中的应用
WO2025185553A1 (zh) * 2024-03-06 2025-09-12 深圳湾实验室 预防和治疗醛代谢紊乱引起的相关疾病的化合物及其用途
WO2026056669A1 (zh) * 2024-09-11 2026-03-19 深圳新锐基因科技有限公司 一种基于ai设计的活性醛类物质抑制剂及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
KR20180116416A (ko) 2016-02-28 2018-10-24 알데이라 테라퓨틱스, 아이엔씨. 사이클로덱스트린으로의 알레르기성 안질환의 치료
CN109152774A (zh) 2016-05-09 2019-01-04 奥尔德拉医疗公司 眼部炎性病症和疾病的组合治疗
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
CN113056353B (zh) 2018-09-25 2022-11-01 奥尔德拉医疗公司 用于治疗干眼病的调配物
WO2020123730A1 (en) * 2018-12-12 2020-06-18 Teva Pharmaceuticals International Gmbh Solid state forms of reproxalap
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2021248031A1 (en) * 2020-06-04 2021-12-09 Aldeyra Therapeutics, Inc. Dry eye disease biomarkers and their use for treatment
WO2023192372A1 (en) * 2022-03-29 2023-10-05 Aldeyra Therapeutics, Inc. Methods of treating sjögren-larssen syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150209333A1 (en) * 2005-05-26 2015-07-30 Aldexa Therapeutics, Inc. Compositions and methods of treating retinal disease
US20150344432A1 (en) * 2012-12-20 2015-12-03 Aldexa Therapeutics, Inc. Peri-carbinols

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111135171B (zh) * 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
KR101646666B1 (ko) * 2015-03-26 2016-08-08 엘지이노텍 주식회사 발광 소자, 이 소자를 포함하는 발광 소자 패키지, 및 이 패키지를 포함하는 조명 장치
KR20180073553A (ko) * 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 알데히드 접합체 및 이의 용도
CN118724806A (zh) * 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150209333A1 (en) * 2005-05-26 2015-07-30 Aldexa Therapeutics, Inc. Compositions and methods of treating retinal disease
US20150344432A1 (en) * 2012-12-20 2015-12-03 Aldexa Therapeutics, Inc. Peri-carbinols

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US12128013B2 (en) 2013-01-23 2024-10-29 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US12240816B2 (en) 2015-08-21 2025-03-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CN111356451A (zh) * 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN113784954A (zh) * 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US12029735B2 (en) 2019-05-02 2024-07-09 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2021136244A1 (zh) * 2019-12-30 2021-07-08 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
CN115551507A (zh) * 2020-04-13 2022-12-30 奥尔德拉医疗公司 用于治疗肺、肝脏和肾脏疾病、病症或病况的喹啉化合物
US12064516B2 (en) 2020-05-13 2024-08-20 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN115697336A (zh) * 2020-05-13 2023-02-03 奥尔德拉医疗公司 药物制剂及其用途
CN114981275B (zh) * 2020-12-29 2023-12-19 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
CN114981275A (zh) * 2020-12-29 2022-08-30 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
WO2022143489A1 (zh) * 2020-12-29 2022-07-07 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
CN115843293A (zh) * 2021-06-25 2023-03-24 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
CN115843293B (zh) * 2021-06-25 2025-01-24 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
WO2025140390A1 (zh) * 2023-12-28 2025-07-03 珠海联邦制药股份有限公司 Rasp抑制剂在制备治疗或预防慢性咳嗽、哮喘及酒精性肝病疾病的药物中的应用
WO2025185553A1 (zh) * 2024-03-06 2025-09-12 深圳湾实验室 预防和治疗醛代谢紊乱引起的相关疾病的化合物及其用途
WO2026056669A1 (zh) * 2024-09-11 2026-03-19 深圳新锐基因科技有限公司 一种基于ai设计的活性醛类物质抑制剂及其应用

Also Published As

Publication number Publication date
US20180050989A1 (en) 2018-02-22
CA3032521A1 (en) 2018-03-01
MX2019001722A (es) 2019-07-04
CO2019001625A2 (es) 2019-04-30
WO2018039192A1 (en) 2018-03-01
JP2019532029A (ja) 2019-11-07
US20200062712A1 (en) 2020-02-27
AU2017317524A1 (en) 2019-02-21
EP3500256A1 (en) 2019-06-26
EP3500256A4 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
KR102664994B1 (ko) 중수소화 화합물 및 이의 용도
US20200062712A1 (en) Aldehyde trapping compounds and uses thereof
JP7080944B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
Dedeoglu et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
EP2114393B1 (en) Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof
Rogov et al. Mitochondrial dysfunctions may be one of the major causative factors underlying detrimental effects of benzalkonium chloride
CN106715455A (zh) 烟酰胺核苷类似物及其药物组合物和用途
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害(それらの症状を含む)の治療
CN102225930A (zh) 治疗与年龄相关的黄斑变性(amd)的方法
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
JP6872805B2 (ja) 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
Kwa et al. Preclinical investigations on broccoli-derived sulforaphane for the treatment of ophthalmic disease
US9730901B2 (en) Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence
CN103037868A (zh) 异类叶升麻苷或其药学上可接受的盐的用途
KR20190035473A (ko) 성분 함량이 변화된 녹차 추출물을 포함하는 인지기능 개선용 조성물
US9439916B2 (en) Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
RU2770534C1 (ru) Гепатопротекторный и антиоксидантный препарат для животных на основе водного раствора фуллерена C60, ресвератрола и бетаина гидрохлорида
CN103908567B (zh) 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用
EP4574142A1 (en) Composition for use in enhancing, boosting, restoring and/or preventing the decline of cognitive functions
JP7490204B2 (ja) 脳機能改善剤
KR100666471B1 (ko) 치매의 예방과 개선 및 기억력 증진용 조성물 및 이를포함하는 건강보조식품
CN122060025A (zh) 一种小分子肽及其在制备抗阿尔茨海默病药物中的应用
HK40019381A (en) Compositions for improving cell viability and methods of use thereof
Fris The effect of single and repeated ultraviolet radiation on the anterior segment of the rabbit eye
Omar Ginkgolides and Neuroprotective Effects 146

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190416